1. An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors. (3rd July 2017) Authors: Gohil, Satyen Harish; Paredes-Moscosso, Solange Rosa; Harrasser, Micaela; Vezzalini, Marzia; Scarpa, Aldo; Morris, Emma; Davidoff, Andrew M.; Sorio, Claudio; Nathwani, Amit Chunilal; Della Peruta, Marco Journal: Oncoimmunology Issue: Volume 6:Number 7(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia. (7th April 2019) Authors: Gohil, Satyen H.; Evans, Rachel; Harasser, Micaela; El‐Kholy, Mohamed; Paredes‐Moscosso, Solange R.; Della Peruta, Marco; Nathwani, Amit C. Journal: British journal of haematology Issue: Volume 186:Number 2(2019) Page Start: 380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Preclinical development of novel humanised ROR1 targeting chimeric antigen receptor T cells and bispecific T-cell engagers. (23rd February 2017) Authors: Gohil, Satyen; Paredes-Moscosso, Solange; Harrasser, Micaela; Davidoff, Andrew; Pule, Martin; Della Peruta, Marco; Nathwani, Amit Journal: Lancet Issue: Volume 389(2017)Supplement 1 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗